{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-23-000061","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.844103+00:00","generated_at":"2026-06-16T16:23:28.576874+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BeiGene reports 2022 revenue of $1.42B, R&D spend $1.64B in STAR Market filing","bullets":["Total revenue $1.416B (2021: $1.176B); China revenue $840M (67.1% margin), Ex-China $576M (98.3% margin).","R&D expenses $1.641B vs $1.459B in 2021; key product spend: Zanubrutinib $127M, Tislelizumab $88.9M, Ociperlimab $106.6M.","Production/sales/inventory: 3.28M vials produced, 2.67M sold, 1.54M in stock as of Dec 31, 2022.","Filed PRC GAAP vs U.S. GAAP reconciliation; differences in share-based comp (accelerated vs straight-line) and lease accounting."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-23-000061","json":"https://secwatch.observer/filing/0001651308-23-000061.json","markdown":"https://secwatch.observer/filing/0001651308-23-000061.md","text":"https://secwatch.observer/filing/0001651308-23-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000061/0001651308-23-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000061/bgne-20230425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T16:23:28.576874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e8097c83929b67b505ef1eabe9bd88ae4e1d5020","claim":"BeOne Medicines Ltd. reported the year ended December 31, 2022 results: revenue 1,415,921.","evidence_excerpt":"For the year ended December 31, 2022 For the year ended December 31, 2021 By Region Revenue COGS Gross Margin ratio Revenue COGS Gross Margin ratio China 840,032 276,729 67.1% 517,173 162,976 68.5% Ex-China 575,889 9,746 98.3% 659,110 1,930 99.7% Total 1,415,921 286,475 1,176,283 164,906","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000061/0001651308-23-000061-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"1,415,921"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}